- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00262834
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVE:
I. Determine the safety and tolerability of vorinostat in women undergoing conventional surgery for newly diagnosed stage I-III breast cancer.
OULINE: This is a multicenter, pilot study.
Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo surgical resection of the tumor on day 0.
After completion of study treatment, patients are followed for 30 days.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- No prior or concurrent hormonal therapy for breast cancer
- Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment (e.g., preoperative/neoadjuvant systemic treatment) for breast cancer
- ECOG 0-2 OR Karnofsky 60-100%
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal
- PT ≤ 14 seconds
- Creatinine normal
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled intercurrent illness
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat
- At least 30 days since prior hormone replacement therapy (e.g., estrogen and/or progestin)
- Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed
- No concurrent birth control pills
- No prior radiotherapy to the ipsilateral breast
- No prior or concurrent radiotherapy for breast cancer
- No prior or concurrent novel therapy for breast cancer
- At least 14 days since prior valproic acid or another histone deacetylase inhibitor
- No other concurrent investigational agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent therapy for this cancer
- WBC ≥ 3,000/mm^3
Exclusion criteria:
- Patients must not be recieving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA.
- Patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA.
- Women who are pregnant.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Arm I
Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
|
Given orally, conventional surgery to follow.
Otros nombres:
Undergo conventional surgery
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants With Adverse Events
Periodo de tiempo: After 3 days of vorinostat
|
Participants were evaluated for adverse events due to vorinostat to assess if it was safe to give the drug prior to surgery.
17 of 25 participants who received vorinostat experienced at least 1 adverse event believed to be related to the study drug; no adverse events were severe, and the treatment was considered safe.
|
After 3 days of vorinostat
|
Change in Tissue Proliferation After 3 Days of Treatment
Periodo de tiempo: After 3 days of vorinostat
|
Change in Ki-67 (a marker of tissue proliferation) by IHC compared to baseline in the treated (22 evaluable samples) or untreated patients (15 evaluable samples) were analyzed between groups.
Ki-67 is a protein in cells that increases as cellsprepare to divide into new cells.
A staining process can measure the percentage of tumor cells that are positive for Ki-67.
The more positive cells there are, the more quickly they are dividing and forming new cells.
|
After 3 days of vorinostat
|
Change in Tissue Apoptosis After 3 Days of Treatment
Periodo de tiempo: Baseline and after 3 day of vorinostat
|
Change in cleaved caspase-3 (a marker of tissue apoptosis) by IHC compared to baseline in the treated (19 evaluable samples) or untreated patients (12 evaluable samples) were analyzed between groups.
Cleaved caspase-3 is a protein in cells involved in apoptosis (cell death).
|
Baseline and after 3 day of vorinostat
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in Tissue Histone Acetylation After 3 Days of Treatment
Periodo de tiempo: Baseline and after 3 day of Vorinostat
|
To evaluate change from baseline in tissue histone acetylation in patients with primary breast cancer who received three days of Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) 300 mg PO bid immediately prior to definitive breast surgery or other primary treatment.
This is measured by Cumulative Methylation Index, which is reported as the sum of all %M for all genes.
%M= (methylated copies divided by methylated + unmethylated copies) x 100.
|
Baseline and after 3 day of Vorinostat
|
Change in Blood (Peripheral Blood Mononuclear Cells) Histone Acetylation After 3 Days of Treatment
Periodo de tiempo: Baseline and after 3 day of Vorinostat
|
To evaluate baseline and change in histone acetylation in polymononuclear cells in patients with primary breast cancer who received three days of SAHA 300 mg PO bid immediately prior to definitive breast surgery or other primary treatment.
|
Baseline and after 3 day of Vorinostat
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Vered Stearns, Johns Hopkins University/Sidney Kimmel Cancer Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- NCI-2009-00098 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- P30CA006973 (Subvención/contrato del NIH de EE. UU.)
- U01CA070095 (Subvención/contrato del NIH de EE. UU.)
- 6914 (Otro identificador: CTEP)
- CDR0000445404 (Otro identificador: Clinical Data Repository (CT.gov))
- SKCCC J0504 (Otro identificador: Johns Hopkins University/Sidney Kimmel Cancer Center)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre vorinostat
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCTerminadoLinfoma folicular | Linfoma de células del manto | Linfoma de zona marginalAustralia
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLCTerminado
-
Virginia Commonwealth UniversityRetirado
-
National Center for Tumor Diseases, HeidelbergMerck Sharp & Dohme LLC; University Hospital HeidelbergTerminado
-
University of CalgaryDesconocido
-
Institut Claudius RegaudMerck Sharp & Dohme LLCTerminadoTumor sólido malignoFrancia
-
Merck Sharp & Dohme LLCYa no está disponibleLinfoma, De Células T, Cutáneo
-
Medical University of GrazTerminadoLeiomiosarcoma | Tumores del estroma endometrial | Carcinosarcomas uterinosAustria
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, Bonn; University of GöttingenTerminadoEnfermedad de AlzheimerAlemania
-
Merck Sharp & Dohme LLCTerminado